A Sweaty Mess: The Botanix Story (ASX: BOT)

Good morning Armchair Army,

Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.

There are not many capital raises that genuinely make me do a double-take. 

But the $45 million raise from Bontanix Pharmaceuticals (ASX: BOT) earlier this year was one.

I had to check whether I had read the terms correctly… twice.

$45 million raised.

45% discount.

1 for 1 option.

Exercisable at the price of the raise.

The type of raise that the company only really gets to do once.

The “attract money… just get it in” raise.

The next company on my Biotech 165 Challenge is Botanix Pharmaceuticals (ASX: BOT).

Their lead product treats excessive underarm sweating.

Useful product.

Especially for anyone who held the stock through that raise.

There's an old saying in markets…

Everything always takes longer and costs more than you expect.

Botanix is living proof.

They did the thing most ASX biotechs only dream about.

They got a drug approved by the FDA.

And yet within 12 months of launch, they were raising at a 45% discount with a free option to boot.

So how does a company go from "approval winner" to "just get the money in" that quickly?

This one is a story about the weight of inflated expectations.

Botanix Pharmaceuticals (ASX: BOT) sells a product called Sofdra, a preventive for hyperhidrosis.

Hyperhidrosis fancy medical term for excessive underarm sweating.

Now, if any of you have met my dad before… he likes to sweat.

If he goes for a run… well, you’d think he’s just gone for a swim.

Three shirts a day.

Now I’m no doctor, but I BET that dad has some form of this condition.

It affects around 10 million people in the US, and that’s the market Botanix is going after.

Botanix didn’t start out as a medical sweat-prevention story.

For years, the company has been working on synthetic cannabinoid treatments for skin conditions such as acne and dermatitis, as well as antimicrobial skin applications.

But after a few years of treading water (like all microcaps do), it went all in on dermatology products.

… all it needed was an asset.

So, instead of waiting years for its own development assets to come to market, Botanix went shopping.

Looking for stranded US assets that it could advance through to market.

That is how Sofdra came into the story.

In 2022, Botanix acquired Sofdra from a struggling NASDAQ-listed company. 

It paid US$5M upfront for a post-Phase 3 drug that had already had more than US$120M spent on it.

The company even bought back the royalty stream and future payments for a ~US$8M upfront payment 12 months later, thereby securing the business's future cash flows.

Aside from one small change from the FDA, everything went smoothly leading up to approvals.

… and on June 20, 2024, the FDA approved Sofdra:

The company followed up with a big $70 million institutional raise to set itself up for the product launch, with first sales in early 2025.

Another $40 million raise… and addition to the ASX-300.

This also happened to be the peak of Botanix's share price…

Selling products into the healthcare system is NOT like a normal sale.

For a drug in the US…

The doctor writes the script.

The insurance company pays for it. 

The pharmacy distributes it.

… and the patient uses it.

It’s not like buying a pair of Nikes at Footlocker. There are multiple customers and stakeholders that any company selling a pharmaceutical product needs to serve.

This is why most Australian companies that bring a drug to market will partner with a company for US sales.

Neuren Pharmaceuticals is a great example of this. 

Building a dedicated sales team in a foreign jurisdiction is a scary proposition for Australian companies (it has been done before, for example, Mesoblast has its own sales team), but it's not as common.

The reality is that Botanix’s CEO, Howie McKibbon, has done this before.

He had been involved in dermatology companies that sold for billions.

It takes a special skill to navigate the incredibly complex challenges to launch a product in the US, namely getting paid and driving sales.

(Because in pharma, they are not the same thing)

Botanix’s sales strategy was to use SendRx (a direct-to-patient pharmacy platform) to control the patient journey.

Instead of a doctor writing a script and hoping the patient sorts it out themselves, SendRx helps with the messy bits…

Insurance checks, approval paperwork, payment, delivery and refill reminders.

That matters because in the US healthcare system, there isn’t just one customer.

But lots (the doctor, the pharmacy, the insurer, and the patient)

Ultimately, the patient decides whether the whole process is easy and affordable enough to be worth doing again.

And then you get a refill.

SendRx was given two goals:

FIRST, make it easier for patients to get Sofdra shipped directly to their door.

SECOND, keep those patients refilling.

The refills are like the software equivalent of “annual recurring revenue”, and drop-off rates are like the “churn”.

The better the platform, the lower the churn.

Reality.

The product launched in February of 2025. 

But it couldn’t meet the market's high expectations for the company.

I spoke to a buy-side analyst whose fund had a modest position in the company, and I asked him about his experience.

He said that the analyst covering the story at the time had wildly ambitious sales forecasts for the product launch, and the sentiment in the market was that they would reach breakeven much quicker.

Also, if you go back through the company archives, there was a correction needed to an article in The West Australian. 

It incorrectly attributed a quote to a company director that Sofdra “would generate anywhere between US$100 million to $200 million in profit”.

While these numbers were retracted, they do give an idea of market expectations going into the launch.

The very first quarter after launch resulted in what you’d expect for a new product launch: 16,000 prescriptions filled and growing at a steady rate…

The stock tanked.

So while this might have been a “base case” result for any new product to market, only a mega bull case outcome would have held up under the weight of inflated expectations:

The challenge was that the company had just raised a bunch of capital beforehand on the expectations of a great launch, and now all of those shareholders were underwater.

Then the 4C came out.

$28 million in outgoings, $3.8 million in revenue.

The market started to do the maths.

At this rate of sales, Botanix would need capital much sooner than the market anticipated.

In the next two quarters, the prescription sales grew.

First 13,000. Then 20,000. Then 25,000.

But so did the burn. 

$13 million. $17 million.

While the company had some cash left and a decent chunk of debt, it was getting very close to the “come raise” territory.

And with the amount of capital that the business needed to finance the sales and ramp up… it was a lot.

So then came the head-turning raise.

$45 million.

45% discount.

1 for 1 option.

Exercisable at the price of the raise.

Botanix got its money in the door, but it paid a high price in terms of dilution.

By April 2026, the cumulative sales prescriptions had reached around 86,000.

Gross revenue was around $118.7M.

Net revenue was around $27.4M.

That gross-to-net gap is a big challenge for Botanix.

Gross revenue sounds meaningful. But net revenue is what matters.  

Botanix can clearly get scripts.

The problem is how much of each script it actually keeps.

For FY26, Canaccord estimates Botanix will sell around 105,000 scripts, at a gross price of US$954 per script.

But the estimated net price per script is only US$216.

That means Botanix is keeping only about 23% of the gross script value. 

The rest gets eaten by the US reimbursement machine.

And then you have the second problem: launching a product is expensive.

Sales reps. Marketing. SendRx. Patient support. API. Manufacturing. Corporate overhead. 

So the issue is not just gross-to-net.

It is gross-to-net challenge PLUS a big cost base as sales ramp up to launch.

This is not the first rodeo for the Botanix team.

Chairman Vince Ippolito and CEO Howie McKibbon had been involved in dermatology companies that sold for billions.

They have a track record of doing it before.

They may be able to do it again.

The challenge is that investors on the ASX like to play the catalyst game, and the capital required to make this business work, I believe, is a big pill for our small healthcare market to swallow.

The stock did run in the lead-up to FDA approvals…

It was a good trade.

But for those investors who were looking to quickly run into a profitable business, the reality was that everything always takes longer and costs more than you think.

But the cost-cutting is underway…

With Botanix working to bring on Piramal as a second API supplier, the company previously flagged potential COGS reductions of 25% to 40%.

(Think of the API as like the ingredients for the product)

But cash is the clock.

And at the burn rate Botanix is running, this $45 million raise might be the last BIG swing that the Australian market affords it before it needs to rethink its strategy.

Sofdra itself is still being prescribed.

The reps are there, the fulfilment platform and the patient support system exist.

Just like any business going through growing pains after launching a new product, the only way out is through.

Boring, relentless execution. 

More scripts. Better net revenue. Higher gross-to-net. Lower burn. Cleaner margins.

… and hopefully avoid another ugly raise.

If Sofdra can support the platform, another dermatology product could make the whole machine more valuable.

But if Sofdra still cannot fund itself, another asset is not a growth strategy. It is another funding problem.

That is the line Botanix has to walk now. 

Botanix did what most biotech companies dream of…

Getting a drug approved and bringing it to market.

But the challenge now is to actually build a business around it.

Sofdra has yet to become a self-funding panacea, and raising the capital required to navigate and launch a product in the complex US market has been challenging.

After the big discount raise, investors are no longer asking: “How big can Sofdra be?”

They are asking… “How much more capital will it take to find out?”

At these levels, expectations of the company are approaching rock bottom.

Which means that any outperformance or hint of profitability should be met with a positive reaction.

Products ARE selling.

More prescriptions month on month, refills are solid, and the trajectory is good.

But it’s just costing them a lot to get there.

I’ll be watching those quarterly cash balances like a hawk to see if the company can get its launch back on track…

A big thank you to Oscar Hogan, who helped me research this article on Botanix.

Also, a big thank you to the CEO, Howie McKibbon, for sharing the Botanix story with me this week.

See you all next week, and have a great weekend.

The Armchair Analyst

But first… 

Happy SpaceX IPO day!

Will be interesting to see how this plays out over the next couple of weeks, a really good (contrarian) take on the IPO that’s worth a read: What I was NOT allowed to say about SpaceX 

Cynata Therapeutics (ASX: CYP) enters a trading halt pending pivotal Phase 3 osteoarthritis AND Phase 2 Graft Versus Host Disease clinical trial results. (CYP)

🪑 Wow, didn’t expect the company to go into a trading halt for BOTH clinical trials.

Interesting strategy. 

It means that the trial results will need to be evaluated together rather than individually.

It de-risks the on-market sentiment if the first trial fails and the second one succeeds. I don’t mind it.

Popcorn out! Five years in the making 🍿

A broad update from TruScreen (ASX: TRU) on the commercial activities for its cervical cancer screening tool across multiple markets in Europe and Asia. (TRU)

🪑 This was one of the most well-written announcements I have seen in a while. As someone completely unfamiliar with TruScreen, I was able to get a full and proper picture of the company and its activities.

With some of these microcaps operating globally, we sometimes forget the steady progress they make in each region. 

Each breadcrumb of progress doesn’t necessarily warrant a standalone announcement, but when seen together, they paint a picture of building a company.

Monash IVF (ASX: MVF) downgrades expectations, FY26 Underlying NPAT guidance to $17-$18M due to a 4.7% decline in Australian ART market activity. (MVF)

Echo IQ Limited (ASX: EIQ) extends its relationship with the Mayo Clinic with a research partnership to evaluate its AI platform for cardiac risk stratification in cancer patients. (EIQ)

🪑 Interesting update, cardiac risk in cancer is a big issue. 

A nice-to-have, but I think the market is holding out for Heart Failure approval and potential reimbursement.

Neurizon Therapeutics (ASX: NUZ) is more than 50% of the way through dosing in its ALS clinical trial. 129 of 240 participants dosed. (NUZ)

🪑 Milestone ticked.

Vitrafy Life Sciences (ASX: VFY) secures A$30 million at A$2.60 per share. (VFY)

Microba Life Sciences (ASX: MAP) raises $5M through a placement at $0.05 per share, with Sonic Healthcare investing $1.5M. (MAP)

🪑Got there in the end!